Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAWN antivirals trial
2020-005911-27Phase 3Terminated
- Sponsor
- KU Leuven
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of molnupiravir and camostat mesilate in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by KU Leuven. Primary endpoint: Time to first self-reported recovery within 30 days. Started Feb 2021; status: terminated.
02
Drugs
molnupiravircamostat mesilate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005911-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005911-27.